Anti-inflammatory drugs for controlling asthma.

Postgrad Med

Division of Allergy and Outpatient Infectious Disease and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Published: September 1998

Anti-inflammatory agents are the first-line treatment for controlling mild persistent, moderate persistent, and severe persistent asthma. The choice of drug and dosage must be individualized to the patient. In general, the glucocorticoids are widely accepted as the most potent and preferred asthma treatment in most adults and some children. Cromolyn, because of its safety and availability in a nebulized form, is the first-line treatment in most young children. The leukotriene inhibitors appear to be effective in mild asthma, but further clinical studies are needed to determine their role more precisely. As the mechanisms of inflammation in asthma are further defined, new pharmaceutical products will be developed to aid in arresting this process.

Download full-text PDF

Source
http://dx.doi.org/10.3810/pgm.1998.09.578DOI Listing

Publication Analysis

Top Keywords

first-line treatment
8
asthma
5
anti-inflammatory drugs
4
drugs controlling
4
controlling asthma
4
asthma anti-inflammatory
4
anti-inflammatory agents
4
agents first-line
4
treatment controlling
4
controlling mild
4

Similar Publications

Diabetes is a growing global health crisis that requires effective therapeutic strategies to optimize treatment outcomes. This study aims to address this challenge by developing and characterizing extended-release polymeric matrix tablets containing metformin hydrochloride (M-HCl), a first-line treatment for type 2 diabetes, and honokiol (HNK), a bioactive compound with potential therapeutic benefits. The objective is to enhance glycemic control and overall therapeutic outcomes through an innovative dual-drug delivery system.

View Article and Find Full Text PDF

Background: 5-Aminosalicylic acid (5-ASA), the first-line therapy for ulcerative colitis, is a poorly soluble zwitterionic drug. Unformulated 5-ASA is thought to be extensively absorbed in the small intestine.

Methods: The pH-dependent solubility of 5-ASA in vitro and the intestinal membrane distribution of 5-ASA and its N-acetyl metabolite (AC-5-ASA) after the oral administration of 5-ASA were examined in fed rats.

View Article and Find Full Text PDF

Currently, artemisinin-based combination therapy is recommended as first-line treatment of uncomplicated malaria. Arylamino alcohols (AAAs) such as mefloquine (MQ) are the preferred partner drugs due to their longer half-life, reliable absorption and strong antimalarial activity. However, the mode of action of MQ remains poorly understood and its neurotoxicity limits its use.

View Article and Find Full Text PDF

Recent advancements in cancer treatment have shown the potential of immune checkpoint blockade (ICB) plus L. therapy in improving survival rates for patients with advanced or metastatic non-small-cell lung cancer (NSCLC). The objective of this study was to investigate factors associated with improved survival in NSCLC patients treated with a combination of ICB and abnobaViscum.

View Article and Find Full Text PDF

Emerging Psychotropic Drug for the Treatment of Trigeminal Pain: Salvinorin A.

Pharmaceuticals (Basel)

November 2024

Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Coyoacán, Ciudad de Mexico 04510, Mexico.

Trigeminal neuralgia (TN) is chronic pain caused by damage to the somatosensorial system on the trigeminal nerve or its branches, which involves peripheral and central dysfunction pain pathways. Trigeminal pain triggers disruptive pain in regions of the face, including within and around the mouth. Besides clinical experiences, translating the language of suffering into scientific terminology presents substantial challenges.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!